Biogen Idec

  • A Winner and 2 Losers in the Battle Over Multiple Sclerosis Treatments

    By Leo Sun - August 13, 2013 | Tickers: BIIB, NVS, TEVA

    There are several major players engaged in multiple sclerosis (MS) treatments. Orally administered treatments have been rapidly replacing older, interferon-based injections, and all eyes were on Biogen Idec’s (NASDAQ: BIIB) newest oral MS treatment, Tecfidera, which was launched in April. At the time, Biogen hadn’t reported its first quarter of Tecfidera sales yet, and investors were still waiting to see if Tecfidera would be the industry changing drug more »

  • This Healthcare Company Is Poised for Growth

    By Nick Chiu - August 9, 2013 | Tickers: BAX, BIIB, HALO

    The performance of Baxter International (NYSE: BAX), the world’s second-largest maker of dialysis products, has been lagging the market with 7.38% gain YTD as of Aug 2, 2013 compared to the 21.91% increase of the S&P 500. However, Baxter is in a transition year as it begins to digests its recent acquisition, Gambro, while preparing for some major new product launches.

    Approved acquisition

    In July, Baxter more »

  • This Company Is Tackling Multiple Sclerosis Head On

    By Kanak Kanti - August 7, 2013 | Tickers: BIIB, GSK, SNY

    Note: This article has been amended to better reflect Lemtrada's market position.

    Currently existing immunomodulatory drugs that treat Multiple Sclerosis only work to treat relapse or attacks, manage symptoms, or modify the course of the disease. MS has no cure. These drugs have too many side effects due to their lack of target specificity. Another class of drugs, recently being developed, are protein based therapies (monoclonal antibodies or mAbs more »

  • Examining an Acquisition That Benefits This Global Healthcare Supplier

    By Anh HOANG - August 5, 2013 | Tickers: BIIB, ELN, PRGO

    Recently, Elan Corporation (NYSE: ELN) ended the fight against bids from Royalty Pharma. Previously, Royalty Pharma had raised its all-cash offer from $5.7 billion to $6.4 billion. Elan still thinks that Royalty Pharma’s offer continued to “grossly undervalue its current business platform and its future prospects, however. Instead, Elan went for an $8.6 billion offer of Perrigo Company (NYSE: PRGO).

    Perrigo’s business snapshot

    Perrigo has more »

  • A Small Company With an Important Portfolio - Part II

    By Kanak Kanti - August 1, 2013 | Tickers: BIIB, NVS, PDLI

    In a previous part of this article, I discussed PDL Biopharma (NASDAQ: PDLI), which has a very interesting patent portfolio. It makes all its money from licensing this portfolio. However, we saw that, considering how this portfolio is very important for the multi-billion dollar monoclonal antibody sector, PDL does not seem to be making as much money as it should. In this section, we will try to figure out why more »

  • A Small Company With an Important Portfolio - Part I

    By Kanak Kanti - August 1, 2013 | Tickers: BIIB, NVS, PDLI

    In this two-part article, I will discuss a very interesting company, PDL BioPharma (NASDAQ: PDLI). This company, relatively unknown and quite small, has a patent portfolio that forms much of the backbone of modern monoclonal antibody technology. In part I, I will discuss PDL, its technology and its market potential. In part II, I will try to figure out why, despite being such an important company, PDL is not being more »

  • Out With the Old, In With the New in Treating MS

    By Ryan Guenette - July 31, 2013 | Tickers: BIIB, NVS, PFE, SNY, TEVA

    Hidden beneath all the numbers and metrics in Biogen Idec's (NASDAQ: BIIB) recent earnings report  is a key confirmation of a shifting market in the treatment of multiple sclerosis. This alteration could yield billions of dollars for companies positioned to take advantage of it. 

    What Happened

    On July 25, Biogen reported second-quarter financial results. Earnings of $2.30 per share and revenue of $1.7 billion both trumped estimates more »

  • Pharmacyclics Set to Glide Higher

    By Terry Chrisomalis - July 31, 2013 | Tickers: BIIB, JNJ, PCYC

    Pharmacyclics (NASDAQ: PCYC) has been a good company to invest in, especially if you had bought shares back in 2009 when it traded around $1 per share. That's not to say it is too late, because this biotech company still has a lot of room to run higher. The reason for the continued run up will be the pipeline that continues to produce results. All of the candidates in more »

  • 3 Biotech Favorites With Noteworthy Drug Data

    By Sherrie Stone - July 29, 2013 | Tickers: ALXN, BIIB, CELG

    Three of the biggest names in biotechnology have reported earnings, and their quarters involved very important drug-related information for investors. In this article, let's look at which of these stocks might be presenting an investment opportunity.

    Far Too Early For Decelerated Growth

    Alexion Pharmaceuticals (NASDAQ: ALXN) has traded higher by 22% over the last month, giving the company a market cap of $21 billion.

    Alexion markets an orphan drug more »

  • A Look at Four Major Players in Multiple Sclerosis Treatments

    By Leo Sun - July 25, 2013 | Tickers: ALKS, BIIB, NVS, XNPT

    Note: A previous version of this article incorrectly referred to XenoPort’s arbaclofen placarbil as an MMF prodrug.

    Multiple sclerosis (MS) is an unpredictable, debilitating disease that affects an estimated 2.1 million people worldwide. Although the disease is not usually fatal, it can have devastating effects on the central nervous system, causing poor coordination, extreme fatigue, blurred vision, blindness, slurred speech and a loss of memory and concentration. MS more »

  • Is Big Biotech Still Growing?

    By Seth Robey - July 24, 2013 | Tickers: AMGN, BIIB, CELG, GILD, IBB

    The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotech ETF (NASDAQ: IBB) up >40% YTD.  The industry continues to climb with development-stage companies cranking out innovative pipelines.   As biotech's biggest company, Amgen (NASDAQ: AMGN) is beginning to look more like Big Pharma than its biotech growth peers.  It has high margins, a comparatively low valuation, and is the only biotech more »

  • This Biotech May Well Buck the Trend

    By Kanak Kanti - July 23, 2013 | Tickers: ALXN, ALKS, BIIB

    For quite some time now the biotech industry has been demonstrating a perceptible inclination towards discovery of drugs for ultra-orphan diseases. Understandably so because orphan drugs demand a high price in the market. In such a scene, Alkermes plc (NASDAQ: ALKS) has adopted a counter-cyclical strategy and chosen to target chronic diseases.

    Alkermes focuses on unmet medical needs in specific patient segments. In simple language, the company is using its more »

  • Should You Buy These 2 Medical Device Stocks?

    By David Gould - July 23, 2013 | Tickers: BAX, BIIB, MDT

    Medical device stocks are an excellent place to be if you are still wary of the macro-economy. They are exposed to inelastic demand and don't have pipelines full of "hit-or-miss" products. Their business models are relatively time-tested, and they often pay a good dividend yield. Below, I review two market leaders and provide my thoughts on recent news about them.

    Baxter (NYSE: BAX) still looks attractive

    Baxter International, the more »

  • A Biotech Betting Everything on a Single Drug

    By Kanak Kanti - July 23, 2013 | Tickers: BIIB, PFE, QCOR

    Despite some negative news, mainly related to reimbursement issues and excess stock booking, Questcor Pharmaceuticals (NASDAQ: QCOR) recently gained solid momentum due to a couple of factors.

    One was the sales growth of Acthar Gel and the addition of BioVectra sales during Q1 2013. The other was the announcement of acquiring exclusive rights of Synacthen from Novartis. Both facts together made the stock go up 15% and more last week more »

  • 3 Drug Companies Treating Multiple Sclerosis

    By usman iftikhar - July 12, 2013 | Tickers: ACOR, BIIB, RCPT

     In the last six months, the NASDAQ biotechnology index has risen by an impressive 26.72%. This means that biotech stocks, on average, had more than double the return of S&P 500 index. These impressive returns are, however, difficult to understand because medical news has not reported any major breakthrough treatment for the various dangerous diseases that exist today. This fact rings a bell in my mind and I more »

  • This Biotechnology Stock Is On The Roll

    By Kanak Kanti - July 10, 2013 | Tickers: BAX, BIIB, PFE

    Biogen Idec (NASDAQ: BIIB) is in the news again; on July 4, 2013 the company presented new data in support of clinical and safety profile for ELOCTATE, its candidate for hemophilia A that it is developing in partnership with Swedish Orphan Biovitrum AB. Earlier, in May this year, the FDA had accepted the company’s Biologics License Application (BLA) for the marketing approval of ELOCTATE. Biogen now has product candidates more »

  • 3 of Biotech’s Best

    By Diane Alter - July 10, 2013 | Tickers: BIIB, CELG, GILD

    It’s been a healthy year-to-date for the biotech sector, with the space logging huge gains above and beyond those of the broad based market. Industry companies have thrived thanks to technological advances that facilitated new discoveries and stoked greater demand for life-enhancing and lifesaving products.

    Industry research firm IBIS World estimates global biotechnology industry revenue will jump 12.7% in 2013, reaching $262 billion. That follows an average annual more »

  • Watch Out for These 3 Biotech Companies

    By Madhukar Dubey - July 4, 2013 | Tickers: AMGN, BIIB, CELG

    The growth of the biotechnology industry is greatly influenced by research and development expenditure.

    This year, the North American players in the biotechnology industry are expected to spend $15 billion. This spending will be in the form of mergers and acquisitions as well as research and development. The North American market is an oligopolistic market where the majority of the revenue is made by a few dominating companies. With such more »

  • 3 Pharma Companies to Buy for the Long Run

    By Madhukar Dubey - July 1, 2013 | Tickers: BIIB, ELN, HSP, VRX

    According to IMS health report, the global pharmaceutical industry is expected to grow at a CAGR of 4.5% in the next five years to reach $1.20 trillion in 2017, from $963 billion in 2012. To keep pace with the industry's growth, pharmaceutical companies are spending on research and development in order to develop new drugs, and are pursuing various expansion strategies. These companies are also looking to more »

  • What’s Next for Elan?

    By Diane Alter - July 1, 2013 | Tickers: BIIB, ELN, PRTA

    Elan's (NYSE: ELN) board unanimously rebuffed a $6.7 billion takeover offer from Royalty Pharma in early June and hired Citigroup to review “several corporate inquiries.” Things are starting to get very interesting. 

    “Both the board and executive management are aligned in exploring all opportunities that maximize the full value of the company for its shareholders,” Elan said in a statement. Apparently, it believes the company is worth much more »

  • Page 1 of 4